Rapid Antimicrobial Susceptibility Test Returns Results within 30 Minutes
|
By LabMedica International staff writers Posted on 29 Nov 2023 |

In 2019, antimicrobial resistance (AMR) was responsible for the deaths of approximately 1.3 million individuals. The conventional approach for testing antimicrobial susceptibility involves cultivating bacterial colonies with antibiotics, a process that is notably time-consuming, often taking several days to gauge bacterial resistance to a spectrum of antibiotics. This delay poses a significant challenge in urgent medical situations, like sepsis, where prompt treatment is crucial. As a result, clinicians are often compelled to either rely on their clinical judgment to prescribe specific antibiotics or administer a broad-spectrum antibiotic regimen. However, the use of ineffective antibiotics can exacerbate infections and potentially lead to increased AMR in the community. Now, researchers have reported significant progress in developing a rapid antimicrobial susceptibility test that can deliver results in as little as 30 minutes, marking a huge improvement over current standard methods.
A team of researchers from the University of Oxford (Oxford, UK) has created a method combining fluorescence microscopy with artificial intelligence (AI) to detect AMR. This technique involves training deep-learning models to scrutinize images of bacterial cells and identify structural changes when exposed to antibiotics. The method proved successful with various antibiotics, demonstrating a minimum accuracy of 80% on a per-cell analysis. The team applied this method to various clinical strains of E. coli, each exhibiting different resistance levels to the antibiotic ciprofloxacin. Impressively, the deep-learning models consistently and accurately identified antibiotic resistance, achieving results at least tenfold faster than current leading clinical methods.
With further development, this rapid testing method has the potential to enable more precise antibiotic treatments, reducing treatment durations, lessening side effects, and helping to curb the growth of AMR. The research team envisions future adaptations of this model for detecting resistance in clinical samples to a broader range of antibiotics. Their goal is to enhance the speed and scalability of this method for clinical application, as well as to modify it for use with various types of bacteria and antibiotics.
“Antibiotics that stop the growth of bacterial cells also change how cells look under a microscope, and affect cellular structures such as the bacterial chromosome,” said Achillefs Kapanidis, Professor of Biological Physics and Director of the Oxford Martin Program on Antimicrobial Resistance Testing. “Our AI-based approach detects such changes reliably and rapidly. Equally, if a cell is resistant, the changes we selected are absent, and this forms the basis for detecting antibiotic resistance.”
Related Links:
University of Oxford
Latest Pathology News
- AI Tool Predicts Patient-Specific Chemotherapy Benefit in Breast Cancer
- AI-Based Pathology Model Guides Chemotherapy Decisions in Breast Cancer
- Biopsy-Based Gene Test Predicts Recurrence Risk in Lung Adenocarcinoma
- New Chromogenic Culture Media Enable Rapid Detection of Candida Infections
- AI-Powered Tool to Transform Dermatopathology Workflow
- AI Tool Predicts Chemotherapy Response from Biopsy Slides
- Sex Differences in Alzheimer’s Biomarkers Linked to Faster Cognitive Decline
- World’s First Optical Microneedle Device to Enable Blood-Sampling-Free Clinical Testing
- Novel mcPCR Technology to Transform Testing of Clinical Samples
- Pathogen-Agnostic Testing Reveals Hidden Respiratory Threats in Negative Samples
- Molecular Imaging to Reduce Need for Melanoma Biopsies
- Urine Specimen Collection System Improves Diagnostic Accuracy and Efficiency
- AI-Powered 3D Scanning System Speeds Cancer Screening
- Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples
- New AI-Driven Platform Standardizes Tuberculosis Smear Microscopy Workflow
- AI Tool Uses Blood Biomarkers to Predict Transplant Complications Before Symptoms Appear
Channels
Clinical Chemistry
view channel
New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
Steroid hormone measurement is a core application of clinical mass spectrometry, which is widely regarded as a diagnostic gold standard. Access to these high-specificity methods has often been constrained... Read more
Study Shows Dual Biomarkers Improve Accuracy of Alzheimer’s Detection
Alzheimer’s disease develops slowly, and biological changes can appear in blood many years before symptoms. While plasma assays for phosphorylated tau offer earlier detection, discerning whether these... Read moreMolecular Diagnostics
view channel
Whole Genome Sequencing in Routine Care Expands Rare Disease Detection
Rare diseases often involve prolonged diagnostic journeys that delay clinical decision-making and complicate family planning. As phenotypes become more heterogeneous, sequencing-based methods are increasingly... Read more
New AI Tool Improves Detection of Genetic Causes in Rare Disorders
Families affected by rare diseases often endure years of inconclusive testing and fragmented referrals before a definitive diagnosis. Despite broad access to genomic sequencing, many patients remain undiagnosed,... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read morePathology
view channel
AI Tool Predicts Patient-Specific Chemotherapy Benefit in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer is typically guided by recurrence risk and population-level averages rather than patient-specific benefit. However, existing clinicopathologic... Read more
AI-Based Pathology Model Guides Chemotherapy Decisions in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer remains a difficult decision because only a subset benefits and many undergo toxicity without gain. Genomic assays can help but are costly,... Read moreTechnology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channel
Takara Bio USA and Hamilton Partner Partner to Automate NGS Library Preparation
Takara Bio USA, Inc. (San Jose, CA, USA), a wholly owned subsidiary of Takara Bio Inc., and Hamilton Company (Reno, NV, USA) announced a development and co-marketing agreement to deliver integrated, automated... Read more








